Article Text

other Versions

PDF
Letter
Ranibizumab treatment for neovascular age-related macular degeneration in patients with good baseline visual acuity (better than 6/12): 12-month outcomes
  1. M S A Raja1,
  2. M Saldana2,
  3. C Goldsmith3,
  4. B J L Burton3
  1. 1Ophthalmology Department, James Paget University Hospital NHS Trust, Great Yarmouth, UK
  2. 2Ophthalmology Department, Guys and St. Thomas Hospital, London, UK
  3. 3Ophthalmology Department, James Paget University Hospital NHS Foundation Trust, Great Yarmouth, UK
  1. Correspondence to Mr Muhammad S A Raja, Ophthalmology Department, James Paget University Hospital NHS Trust, Great Yarmouth NR31 6LA, UK; docraja{at}hotmail.com

Statistics from Altmetric.com

Intravitreal Ranibizumab (Lucentis) monotherapy is currently the standard of care for neovascular age-related macular degeneration (AMD), supported by well-conducted clinical trials and non-randomised studies.1–4 Visual and anatomical outcomes are definitely better than Verteporfin Photodynamic therapy (PDT), but the treatment comes at a cost.5 The current goal of anti-vascular endothelial growth factor (VEGF) agents is to stabilise and/or improve vision. The natural history of untreated disease leads to irreversible visual loss in majority of patients.6 Current evidence-based literature is lacking for patients with “active, symptomatic” neovascular AMD with centre involvement and visual acuity better than 6/12 (20/40) at presentation. We present 12-month outcomes for neovascular AMD patients treated with Lucentis and presenting baseline visual acuity better than (6/12).

Fourteen eyes of 14 patients with neovascular AMD were …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.